LGND Stock Summary and Trading Ideas (Ligand Pharmaceuticals | NASDAQ:LGND)

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ligand Pharmaceuticals trades on the NASDAQ stock market under the symbol LGND.

As of January 8, 2026, LGND stock price climbed to $200.07 with 114,722 million shares trading.

LGND has a beta of 0.81, meaning it tends to be less sensitive to market movements. LGND has a correlation of 0.21 to the broad based SPY ETF.

LGND has a market cap of $3.94 billion. This is considered a Mid Cap stock.

Last quarter Ligand Pharmaceuticals reported $115 million in Revenue and $3.09 earnings per share. This beat revenue expectation by $57 million and exceeded earnings estimates by $1.52.

In the last 3 years, LGND traded as high as $212.49 and as low as $49.24.

The top ETF exchange traded funds that LGND belongs to (by Net Assets): IJR, VTI, IWM, VB, VBR.

LGND has outperformed the market in the last year with a price return of +80.9% while the SPY ETF gained +18.2%. LGND has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.4% and +1.5%, respectively, while the SPY returned +2.7% and -0.1%, respectively.

LGND support price is $195.86 and resistance is $204.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LGND shares will trade within this expected range on the day.